GSTM1 and chronic kidney disease: Hence, consistent with the initial recommendation, we considered that “ESA treatments are not recommended for pre-dialysis CKD patients with a history of cancer (certainty of evidence is weak).” However, this report was based on only one study, and the intervention group had a high target Hb level of 13 g/dL, which may have emphasized the mortality outcome.